ArticleThe journal of obstetrics and gynaecology research2021
Clinical analysis of uterine intravenous leiomyomatosis: A retrospective study of 260 cases.
Article in The journal of obstetrics and gynaecology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical analysis of nine cases of uterine intravenous leiomyomatosis and review of the literature.Medicine · 2026Review
- Article
- Ultrasonic typing and diagnostic value of intravenous leiomyomatosis: a single-center retrospective study.Frontiers in oncology · 2026Article
- Multidisciplinary management of intravenous leiomyomatosis extending to the inferior vena cava and heart: a case series.BMC cardiovascular disorders · 2025Article
- Intravenous Leiomyomatosis in a 20-Year-Old Nulliparous Woman: Atypical Presentation and Radiological Investigation.Cureus · 2025Article
- Ultrasound diagnostic value and clinical analysis of 61 uterine intravenous leiomyomatosis cases.Quantitative imaging in medicine and surgery · 2025Article
- Intravenous leiomyomatosis presenting as Budd-Chiari syndrome: a case report and literature review.Orphanet journal of rare diseases · 2025Review
- Intravenous leiomyomatosis involving the inferior vena cava and right atrium with postoperative pulmonary embolism: a case report.Frontiers in surgery · 2025Article
- Pathological characteristics and clinical prognostic analysis of intravenous leiomyomatosis: a retrospective study of 43 cases.Frontiers in medicine · 2025Article
- Ultrasound Appearance of Intravascular Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Case Report.Diagnostics (Basel, Switzerland) · 2024Article
- Analysis of risk factors for post-operative recurrence or progression of intravenous leiomyomatosis.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- MR imaging findings of stage I intravenous leiomyomatosis: a retrospective single-center study in 19 cases.Abdominal radiology (New York) · 2024Article
- Update on clinical characteristics and molecular insights for uterine intravenous leiomyomatosis (Review).Oncology letters · 2024Review
- Intravascular Leiomyoma Considered Preoperatively as Uterine Sarcoma: A Rare Case.Women's health reports (New Rochelle, N.Y.) · 2024Article
- Ultrasound findings of ovarian intravenous leiomyomatosis: a case report.Frontiers in oncology · 2024Article
- Clinical features and prognostic factors analysis of intravenous leiomyomatosis.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
methodsWe collected the clinical data of 260 patients admitted to the hospital from April 2003 to September 2019 with pathologically confirmed intravenous leiomyomatosis (IVL) and followed up with these patients regularly. Univariate and multivariate logistic regression analyses were carried out on the relevant recurrence factors.
resultsA total of 166 patients were regularly followed up, the median follow-up time was 36 (range 2-168) months, 14 (5.4%) patients eventually relapsed, and the median recurrence time was 8.5 (range 2-42) months. The univariate analysis showed that age (p = 0.003) and surgical type (p < 0.001) were associated with recurrence, and multivariate regression analysis demonstrated that surgical type was the only factor associated with recurrence (p < 0.001, OR 20.01).
conclusionsThe use of gonadotrophin releasing hormone agonist (GnRHa) cannot reduce the postsurgical recurrence rate of patients with UIVL. Compared to total hysterectomy and bilateral salpingo-oophorectomy (TH-BSO), total hysterectomy (TH) does not increase the odds of recurrence, but the chance of recurrence with tumorectomy (TE) is 20 times higher than that of TH-BSO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.